牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on January 31, 2024, will not undergo review by the commission. The SEC's communication, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, was dated February 5, 2024. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and copied Ross McAloon on the correspondence.
Arcutis Biotherapeutics, a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on January 31, 2024, will not undergo review by the commission. The SEC's communication, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, was dated February 5, 2024. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and copied Ross McAloon on the correspondence.
美國證券交易委員會（SEC）已告知生物製藥公司Arcutis Biotherapeutics，其於2024年1月31日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會致Arcutis總裁兼首席執行官渡邊託德·富蘭克林的信函日期爲2024年2月5日。美國證券交易委員會還提醒該公司，無論美國證券交易委員會的審查程序如何，其披露的準確性和充分性都有責任。美國證券交易委員會爲任何其他問題提供了聯繫信息，並在信函中複製了羅斯·麥卡隆。
美國證券交易委員會（SEC）已告知生物製藥公司Arcutis Biotherapeutics，其於2024年1月31日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會致Arcutis總裁兼首席執行官渡邊託德·富蘭克林的信函日期爲2024年2月5日。美國證券交易委員會還提醒該公司，無論美國證券交易委員會的審查程序如何，其披露的準確性和充分性都有責任。美國證券交易委員會爲任何其他問題提供了聯繫信息，並在信函中複製了羅斯·麥卡隆。
有用
沒用
